Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Dunleavy Website

Kieron M. Dunleavy, M.D.

Selected Publications
1)  Dunleavy K, Kohler DR, Wilson WH.
Non Hodgkin Lymphoma. In: Hematology-Oncology Therapy. Volume 1.
New York: McGraw Hill; 2007. p. 308-346 [Book Chapter]
2)  Healey-Bird B, Dunleavy K, White T, Wilson WH, Wiestner A.
A Patient With Stage IV Mantle Cell Lymphoma Treated With Bortezomib/DA-EPOCH/Rituximab.
Case Studies in Lymphoma. 5: No.2, 2007. Full Text Article. [Journal]
3)  Dunleavy K, Wilson WH, Jaffe ES.
Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications.
Curr. Opin. Hematol. 14: 348-53, 2007. [Journal]
4)  Dunleavy K, Wilson WH.
Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy.
Leuk. Lymphoma. 48: 449-51, 2007. [Journal]
5)  Dunleavy K, Davis RE, Landgren O, Staudt LM, Wilson WH.
BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?.
Blood. 109: 843-4; discussion 844-5, 2007. [Journal]
6)  Dunleavy K, Staudt LM, Wilson WH.
The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma.
Leuk. Lymphoma. 48: 1061-3, 2007. [Journal]
7)  Dunleavy K, Wilson W.
Malignant Lymphomas. In: American College of Physicians Medicine Textbook. Volume 2.
New York: WebMD; 2006. p. 2591-2608 [Book Chapter]
8)  Dunleavy K, Kass E, Gill R, Wilson WH.
Lymphomas of the Head and Neck.
Emedicine. Otolaryngology and Facial Plastic Surgery. ., 2006. Full Text Article. [Journal]
9)  Dunleavy K, Wilson WH.
Primary intraocular lymphoma: current and future perspectives.
Leuk. Lymphoma. 47: 1726-7, 2006. [Journal]
10)  Dunleavy K, Wilson WH, Kaplan LD.
The case for rituximab in AIDS-related lymphoma.
Blood. 107: 3014-5, 2006. [Journal]
11)  Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH.
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
Blood. 106: 795-802, 2005. [Journal]
12)  Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH.
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.
Blood. 105: 496-502, 2005. [Journal]
13)  Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH.
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.
Nat. Med. 11: 986-91, 2005. [Journal]
14)  Dunleavy K, Staudt L, Wilson W.
Clinical Application of Molecular Profiling in Lymphomas. In: Progress in Oncology (Devita VT, Hellman S, Rosenberg S). Volume 1.
Sudbury, Massachusetts: Jones and Bartlett; 2004. p. 198-220 [Book Chapter]
15)  Nguyen JD, Dunleavy K, Carrasquillo JA, Chen CC.
F-18 fluorodeoxyglucose positron emission tomographic imaging in a patient with persistent hiccups.
Clinical nuclear medicine. 29: 35-6, 2004. [Journal]
16)  Stevens WT, Pittaluga S, Dunleavy K, Wilson WH, Leitman SF, Bolan CD.
Transfusion medicine illustrated. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma.
Transfusion. 44: 1679, 2004. [Journal]
17)  McDermott RS, Maher MM, Dunleavy K, O'Keane CJ, Stack JP, Carney DP.
Unusual presentations of lymphoma: Case 2. Non-Hodgkin's lymphoma presenting as liver disease.
J. Clin. Oncol. 20: 1943-6, 2002. [Journal]

This page was last updated on 1/8/2008.